Par Drugs And Chemicals share price & results
- Jun 2026
- Jun 2026
Bhavnagar (Gujarat) manufacturer of antacid-segment Active Pharmaceutical Ingredients (APIs) and Fine Chemicals, now exiting this business to diversify into real estate/construction, capital markets and renewable energy.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 31.3 | +20.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 20.4 | +6.7 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 4.7 | +41.4% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | 13.73 | −2.8 pts | Trailing twelve months | TTM to Jun 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | 13.52 | −1.1 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 4.28 | −2.2 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance +8.8% 1Y
1Y: ₹100.62 on 24 Oct 2025 → ₹109.49. High ₹168.25 (2 Sept 2026), low ₹78.58 (30 Mar 2026).
- Previous close
- ₹104.28
- Market cap
- ₹155 Cr
- 52-week range
- ₹78.58 – ₹168.25
- One year
- +6.13%
- Price to earnings (TTM to Jun 2026)
- 10.70×
- Return on equity (TTM to Jun 2026)
- 13.73%
Overview
- Symbol
- NSE:PAR
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Par Drugs And Chemicals Limited does
Based on the company's own presentations, annual report and earnings calls.
Par Drugs and Chemicals Limited manufactures Active Pharmaceutical Ingredients (APIs) and Fine Chemicals from a single site at Chitra, Bhavnagar (Gujarat), producing the full range of antacid-segment molecules (e.g., Magnesium Hydroxide, Sucralfate, Magnesium Trisilicate) along with industrial fine chemicals used in ceramics, agrochemicals and detergents. It sells both domestically and to roughly 16 export markets through a network of dealers and agents. Following shareholder approval at an Extraordinary General Meeting on 12 February 2025, the company has decided to exit its existing pharmaceutical and chemical operations and diversify into real estate & construction, capital markets, and clean & renewable energy.
Segments
- API (Active Pharmaceutical Ingredients)
- Fine Chemicals
- Manufacturing facility
- 1 site (Chitra, Bhavnagar, Gujarat) with 4 dedicated manufacturing blocks
- Installed capacity
- ~9,700 MTPA
- Product portfolio
- 15 APIs + 10 Fine Chemicals (25 products)
- Customer base
- 260+ customers (FY23)
- Dealer network (India)
- 40+ dealers (FY23)
- Agent network (global)
- 13+ agents (FY23)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: +41% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 35 | 21 | 22 | 26 | 29 | 29 | 20 | 31 |
| Expenses | 23 | 20 | 20 | 22 | 23 | 23 | 18 | 25 |
| Operating profit | 11 | 1 | 2 | 4 | 6 | 6 | 1 | 6 |
| Operating margin | 32.9% | 6.7% | 10.9% | 13.7% | 21.1% | 20.6% | 7.3% | 20.4% |
| Other income | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 11 | 1 | 2 | 4 | 6 | 6 | 1 | 6 |
| Tax rate | 25.1% | 24.4% | 27.6% | 25.7% | 25.6% | 25.5% | −3.6% | 25.6% |
| Net profit | 9 | 1 | 2 | 3 | 4 | 5 | 1 | 5 |
| EPS (₹ per share) | 6.99 | 0.47 | 1.34 | 2.71 | 3.36 | 3.90 | 0.69 | 3.83 |
| Line item | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 96 | 101 | 104 |
| Expenses | 73 | 81 | 87 |
| Operating profit | 23 | 20 | 17 |
| Other income | 0 | 2 | 4 |
| Interest | 0 | 0 | 0 |
| Depreciation | 3 | 4 | 4 |
| Profit before tax | 20 | 18 | 17 |
| Net profit | 15 | 13 | 13 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 48 | 59 | 73 | 87 | 94 | 100 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 |
| Other liabilities | 19 | 18 | 16 | 20 | 21 | 17 |
| Total liabilities | 79 | 89 | 102 | 119 | 128 | 129 |
| Fixed assets | 34 | 38 | 41 | 39 | 38 | 36 |
| Capital work in progress | 0 | 0 | 0 | 0 | 0 | 1 |
| Investments | 0 | 0 | 0 | 25 | 27 | 27 |
| Other assets | 44 | 50 | 60 | 55 | 63 | 65 |
| Total assets | 79 | 89 | 102 | 119 | 128 | 129 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | 12 | 8 | 13 | 20 | 16 | 16 |
| Cash from investing | 0 | -3 | -7 | -6 | -25 | -2 |
| Cash from financing | 2 | -10 | 0 | 0 | 0 | 0 |
| Net cash flow | 14 | -5 | 6 | 14 | -9 | 14 |
| Free cash flow | 12 | 4 | 6 | 14 | 15 | 14 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 75 | 90 | 65 | 52 | 60 | 42 |
| Inventory days | 50 | 60 | 49 | 45 | 58 | 45 |
| Days payable | 112 | 135 | 73 | 58 | 104 | 69 |
| Cash conversion cycle | 13 | 14 | 40 | 40 | 15 | 19 |
| Working capital days | 24 | 61 | 50 | 40 | 39 | 31 |
| Return on capital employed | 25.0% | 22.0% | 23.0% | 25.0% | 18.0% | 15.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
What the price assumes
- Growth the price implies
- A decline
- for 7 years, fading to 4%
- It has actually compounded at
- Not enough history
- The gap
- —
- between what it did and what it must do
Ownership
Who owns it
Promoters hold 73.41% as of Jun 2026; institutions added 0.09 pts since Mar 2026.
- Promoters 73.41%
- Foreign institutions 0.00%
- Domestic institutions 0.09%
- Public 26.51%
Who is on the register
Named in the Jun 2026 filing
Every holder of Par Drugs And Chemicals Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| 21.88% | unchanged | |
| 21.50% | unchanged | |
| 20.52% | unchanged | |
| 6.52% | unchanged | |
| 1.80% | unchanged | |
| 1.54% | unchanged | |
| 1.44% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Par Drugs And Chemicals Limited
Free account: one company. Everything above stays public.
Write why you follow Par Drugs And Chemicals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Par Drugs And Chemicals Limited
Guides on how to read this kind of business and the numbers that matter.